A Phase 1 Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Tolerability of a Single Intravenous Infusion of BX-U001, a Human Umbilical Cord Tissue Derived Mesenchymal Stem Cell Product, for Refractory Rheumatoid Arthritis
Latest Information Update: 19 Feb 2025
At a glance
- Drugs BX U001 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Baylx
Most Recent Events
- 12 Feb 2025 Planned End Date changed from 20 Feb 2026 to 20 Feb 2027.
- 12 Feb 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.
- 12 Feb 2025 Planned initiation date changed from 1 Dec 2024 to 1 Dec 2025.